SOPHiA GENETICS Reports Third Quarter 2026 Results

SOPHiA GENETICS reported Q3 2026 revenue of $24.3 million, up 25% year over year, while adjusted EBITDA loss narrowed 31% to $6.1 million; net loss was $20.3 million, up 1%. The company expects full-year revenue at the upper end of its prior $94 million–$96 million guidance range, with adjusted EBITDA loss forecast at $29 million–$32 million versus $41.5 million in FY 2025. Growth included 41% U.S. revenue growth, 118% net dollar retention and 30 new genomics customers; management cited year-end foreign-exchange movements as a potential Q4 revenue headwind and reaffirmed its target of positive adjusted EBITDA in H2 2027.

Analysis

The operating signal is stronger than the headline growth rate alone: customer expansion and rising analysis volumes point to platform adoption, while new accounts are a lagged catalyst rather than near-term revenue. The key underwriting question is whether usage and BioPharma programs convert into durable gross-profit dollars fast enough to absorb a still-large operating cost base. Slight gross-margin compression, rising operating expenses, and adjusted EBITDA exclusions—including recurring stock compensation and social charges, plus litigation—make the path to second-half 2027 profitability less proven than the adjusted loss trend suggests.

Cash increased, but the nine-month operating cash outflow plus capitalized development spending shows ongoing funding needs; much of the cash increase came from equity issuance. That lowers near-term liquidity risk but raises dilution risk if the ramp slips. Currency is a near-term reporting headwind, not a demand signal; assess constant-currency growth separately.

The AstraZeneca CDx agreements and other pharma work validate the channel, but deal economics, launch timing, and revenue concentration are undisclosed. Treat them as option value until contribution and ramp are visible. SOPHiA’s Guardant Health litigation is a continuing cost and potential commercial distraction; it also complicates comparisons that exclude litigation expense. Near term, expectations around guidance and profitability may dominate the stock response. Over 6–18 months, sustained customer usage and improved cash conversion matter more than signed-customer counts. No valuation data is supplied, so the release alone does not establish an attractive entry price.

Key Decisions for Investors

• Do not chase an earnings-driven move in SOPH without checking the post-release price reaction and valuation. Consider a small, staged long only on weakness if subsequent quarters confirm revenue conversion from new accounts and continued improvement in operating cash use; thesis fails if guidance is cut or customer expansion does not translate into revenue.
• Track quarterly constant-currency revenue, gross margin, and cash flow including capitalized development costs. A rising adjusted EBITDA loss or worsening cash burn despite growth would challenge the scalability narrative.
• Treat the AZN CDx relationship as a strategic validation signal, not a quantified earnings catalyst for AstraZeneca: program economics and launch contribution are not disclosed. No AZN trade is supported by this release alone.
• Monitor Guardant Health litigation costs and developments, along with any change in SOPH financing or share issuance. A material adverse legal development or renewed equity funding need would weaken the SOPH long thesis.